There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Autolus Therapeutics (AUTL – Research Report) and Citius Pharmaceuticals (CTXR – Research Report) with bullish sentiments.
Autolus Therapeutics (AUTL)
Needham analyst Gil Blum maintained a Buy rating on Autolus Therapeutics today and set a price target of $9.00. The company’s shares closed last Friday at $4.50.
According to TipRanks.com, Blum is a 3-star analyst with an average return of
Autolus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $9.33.
See the top stocks recommended by analysts >>
Citius Pharmaceuticals (CTXR)
Maxim Group analyst Michael Okunewitch maintained a Buy rating on Citius Pharmaceuticals yesterday and set a price target of $4.00. The company’s shares closed last Friday at $0.66, close to its 52-week low of $0.60.
According to TipRanks.com, Okunewitch is ranked 0 out of 5 stars with an average return of
Citius Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AUTL:
- Autolus Therapeutics Shares Q1 Results and Corporate Update
- Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
- Options Volatility and Implied Earnings Moves Today, May 17, 2024
- Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
- Autolus files to delay quarterly report, cancels earnings call
